Pfizer plant in Kansas repeatedly hit with form 483 infractions
Since 2012, Pfizer's Hospira plant in Kansas has received eight citations including infractions for cardboard in samples and failures to conduct investigations into discrepancies in batches of finished products (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - December 11, 2018 Category: Pharmaceuticals Source Type: news

Generic Drugmaker to Sell Alternative to EpiPen Injectors
TRENTON, N.J. (AP) — Generic drugmaker Sandoz announced plans Thursday to start selling an alternative to the EpiPen in the U.S. early next year. The EpiPen injector is used to halt life-threatening allergic reactions to insect bites, nuts and other foods. Brand-name EpiPen, which dominates the market, has been in short supply since spring because of production problems. Sandoz will sell prefilled syringes with the same medicine, the hormone epinephrine, under the name Symjepi. The price will be $250 for two, without insurance. Two generic versions of EpiPen are sold in the U.S. for $300 a pair, including one from Ep...
Source: JEMS Patient Care - December 7, 2018 Category: Emergency Medicine Authors: Linda A. Johnson, AP Medical Writer Tags: Patient Care News Source Type: news

Generic Drugmaker to Sell Alternative to EpiPen Injectors
TRENTON, N.J. (AP) — Generic drugmaker Sandoz announced plans Thursday to start selling an alternative to the EpiPen in the U.S. early next year. The EpiPen injector is used to halt life-threatening allergic reactions to insect bites, nuts and other foods. Brand-name EpiPen, which dominates the market, has been in short supply since spring because of production problems. Sandoz will sell prefilled syringes with the same medicine, the hormone epinephrine, under the name Symjepi. The price will be $250 for two, without insurance. Two generic versions of EpiPen are sold in the U.S. for $300 a pair, including one from Ep...
Source: JEMS: Journal of Emergency Medical Services News - December 7, 2018 Category: Emergency Medicine Authors: Linda A. Johnson, AP Medical Writer Tags: Patient Care News Source Type: news

Generic Drugmaker To Sell Cheaper Alternative To EpiPen Injectors
TRENTON, N.J. (AP) — Generic drugmaker Sandoz announced plans Thursday to start selling an alternative to the EpiPen in the U.S. early next year. The EpiPen injector is used to halt life-threatening allergic reactions to insect bites, nuts and other foods. Brand-name EpiPen, which dominates the market, has been in short supply since spring because of production problems. Sandoz will sell prefilled syringes with the same medicine, the hormone epinephrine, under the name Symjepi. The price will be $250 for two, without insurance. Two generic versions of EpiPen are sold in the U.S. for $300 a pair, including one from Ep...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - December 7, 2018 Category: Consumer Health News Authors: Health – CBS Boston Tags: Health News EpiPen Local TV Source Type: news

Peninsula drug maker to pay $360M to settle Justice Department claims
Actelion Pharmaceuticals US Inc. will pay $360 million to settle U.S. Department of Justice claims that the company illegally funded a foundation and steered Medicare customers to the foundation, leaving taxpayers to pick up much of the cost as it hiked prices for its pulmonary arterial hypertension drugs. Arrangements between drug makers and nonprofit foundations, which cover a portion of drug costs, have gained attention over the past couple of years. Pfizer Inc. (NYSE: PFE), for example, paid… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - December 6, 2018 Category: Pharmaceuticals Authors: Ron Leuty Source Type: news

Peninsula drug maker to pay $360M to settle Justice Department claims
Actelion Pharmaceuticals US Inc. will pay $360 million to settle U.S. Department of Justice claims that the company illegally funded a foundation and steered Medicare customers to the foundation, leaving taxpayers to pick up much of the cost as it hiked prices for its pulmonary arterial hypertension drugs. Arrangements between drug makers and nonprofit foundations, which cover a portion of drug costs, have gained attention over the past couple of years. Pfizer Inc. (NYSE: PFE), for example, paid… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - December 6, 2018 Category: Biotechnology Authors: Ron Leuty Source Type: news

Pfizer reaches a global agreement with AbbVie
Pfizer Inc. (NYSE:PFE) has signed licensing agreements with AbbVie, resolving all global intellectual property matters for Pfizer's proposed adalimumab biosimilar. Under the terms of the agreements, AbbVie grants Pfizer a non-exclusive patent license for the use and sale of Pfizer's proposed adalimumab biosimilar for many countries around the world. (Source: World Pharma News)
Source: World Pharma News - December 4, 2018 Category: Pharmaceuticals Tags: Featured Pfizer Business and Industry Source Type: news

UK Supreme Court ruling over pregabalin could cost Pfizer £500m
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - December 1, 2018 Category: Drugs & Pharmacology Source Type: news

AbbVie Announces HUMIRA(R) (adalimumab) Global Patent License with Pfizer
NORTH CHICAGO, Ill., Nov. 30, 2018 -- (Healthcare Sales & Marketing Network) -- AbbVie (NYSE: ABBV) announced today patent license agreements with Pfizer over its proposed biosimilar adalimumab product. Under the terms of the agreements, AbbVie will grant... Biopharmaceuticals, Generics, Licensing AbbVie, Pfizer, biosimilar, HUMIRA, adalimumab (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 30, 2018 Category: Pharmaceuticals Source Type: news

China's online healthcare platform jianke.com enters into strategic collaboration with Pfizer
Jianke.com, China's online healthcare platform, yesterday announced during the Jianke Doctor Rebrand& 2018 Jianke Partners'Conference in Shanghai that they will be entering into a strategic partnership with US-based global pharmaceutical leader Pfizer. (Source: mobihealthnews)
Source: mobihealthnews - November 30, 2018 Category: Information Technology Source Type: news

Pfizer scores six month extension for Lyrica patent
The FDA has handed a consolation prize to Pfizer, which is on the cusp of completely losing its patent on the company ’s best-selling drug, Lyrica. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - November 29, 2018 Category: Pharmaceuticals Source Type: news

Roche Buys U.S. Biotech Jecure in Race for Liver Disease Drugs Roche Buys U.S. Biotech Jecure in Race for Liver Disease Drugs
Swiss drugmaker Roche is buying U.S.-based Jecure Therapeutics, joining Pfizer, Gilead Sciences and Novartis in pursuit of new drugs to treat fatty liver disease.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 29, 2018 Category: Consumer Health News Tags: Gastroenterology News Source Type: news

Another EpiPen Is Now on the Market
Teva Pharmaceuticals has finally launched its generic version of Mylan’s EpiPen.  The Petah, Tikvah, Israel-based company’s emergency allergy shot will be priced at $300 – the same as Mylan’s generic. Teva received approval for its version of EpiPen in August. The generic will be available in limited supply and the company will launch a lower-dose - the EpiPen Jr. sometime next year, the company said. “We’re pleased to provide access to Epinephrine Injection (Auto-Injector) for patients who may experience...
Source: MDDI - November 27, 2018 Category: Medical Devices Authors: Omar Ford Tags: Business Source Type: news

Roche buys U.S. biotech Jecure in race for liver disease drugs
Swiss drugmaker Roche is buying U.S.-based Jecure Therapeutics, joining Pfizer, Gilead Sciences and Novartis in pursuit of new drugs to treat fatty liver disease. (Source: Reuters: Health)
Source: Reuters: Health - November 27, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Pfizer nabs fourth oncology approval in two months
The FDA has approved Pfizer ’s new drug, Daurismo, for patients with acute myeloid leukemia. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - November 26, 2018 Category: Pharmaceuticals Source Type: news

Pfizer Inc. Issues A Voluntary Nationwide Consumer Level Recall of Six Lots of Thermacare ® Heatwraps Due to Leaking Wraps With The Potential For Skin Injuries
Pfizer Consumer Healthcare, a division of Pfizer Inc., is voluntarily recalling six lots of ThermaCare ® HeatWrap product to the consumer level. Pfizer Consumer Healthcare initiated this recall because product from these lots has a potential to leak ingredients that are contained in the heat cell wrap. (Source: Food and Drug Administration)
Source: Food and Drug Administration - November 26, 2018 Category: Food Science Source Type: news

Pfizer Inc. Issues A Voluntary Nationwide Consumer Level Recall of Six Lots of Thermacare ® Heatwraps Due to Leaking Wraps With The Potential For Skin Injuries
Pfizer Consumer Healthcare, a division of Pfizer Inc., is voluntarily recalling six lots of ThermaCare ® HeatWrap product to the consumer level. Pfizer Consumer Healthcare initiated this recall because product from these lots has a potential to leak ingredients that are contained in the heat cell wrap. (Source: Food and Drug Administration)
Source: Food and Drug Administration - November 26, 2018 Category: Food Science Source Type: news

FDA Approves New Oral Drug for AML FDA Approves New Oral Drug for AML
Pfizer's Daurismo Improves Overall Survival in Newly Diagnosed Patients Aged 75+FDA Approvals (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - November 21, 2018 Category: Drugs & Pharmacology Tags: Hematology-Oncology News Alert Source Type: news

FDA approves new blood cancer treatment from Pfizer
The U.S. Food and Drug Administration on Wednesday approved Pfizer Inc's drug to treat a form of blood cancer in newly diagnosed patients as a combination therapy. (Source: Reuters: Health)
Source: Reuters: Health - November 21, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

FDA approves Pfizer's treatment for rare blood cancer
The U.S. Food and Drug Administration said on Wednesday it approved Pfizer Inc's treatment for a rare form of blood cancer in some adults. (Source: Reuters: Health)
Source: Reuters: Health - November 21, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Drugmaker Pfizer plans to raise prices on 41 prescription drugs
"Navigating the drug pricing maze can be very confusing and frustrating. Bob Herman, health care business reporter for Axios, joined CBSN to discuss his article on drug pricing in America. " (Source: Health News: CBSNews.com)
Source: Health News: CBSNews.com - November 20, 2018 Category: Consumer Health News Source Type: news

Morning Break: Pfizer vs Trump; Florida vs Opioid Pharmacies; Facebook and Suicide
(MedPage Today) -- Health news and commentary from around the Web gathered by the MedPage Today staff (Source: MedPage Today Psychiatry)
Source: MedPage Today Psychiatry - November 19, 2018 Category: Psychiatry Source Type: news

Merck KGaA, Pfizer drug fails late-stage cancer trial
Merck KGaA and Pfizer announced that the cancer immunotherapy avelumab did not meet the primary endpoints of a phase 3 ovarian cancer trial. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - November 19, 2018 Category: Pharmaceuticals Source Type: news

Merck KGaA, Darmstadt, Germany, and Pfizer Provide Update on Avelumab in Platinum-Resistant/Refractory Ovarian Cancer
DARMSTADT, Germany and NEW YORK, November 19, 2018 -- (Healthcare Sales & Marketing Network) -- Merck KGaA, Darmstadt, Germany, and Pfizer Inc. (NYSE: PFE) today announced that the Phase III JAVELIN Ovarian 200 trial evaluating avelumab* alone or in combi... Biopharmaceuticals, Oncology Merck KGaA, Pfizer, avelumab, ovarian cancer (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 19, 2018 Category: Pharmaceuticals Source Type: news

Merck and Pfizer provide update on avelumab in platinum-resistant/refractory ovarian cancer
Merck and Pfizer Inc. (NYSE: PFE) today announced that the Phase III JAVELIN Ovarian 200 trial evaluating avelumab* alone or in combination with pegylated liposomal doxorubicin (PLD), a type of chemotherapy, compared with PLD did not meet the prespecified primary endpoints of overall survival (OS) or progression-free survival (PFS) in patients with platinum-resistant or -refractory ovarian cancer. (Source: World Pharma News)
Source: World Pharma News - November 19, 2018 Category: Pharmaceuticals Tags: Featured Merck Group Business and Industry Source Type: news

Former pharma executive who joined HHS to help lower drug prices found bludgeoned to death in D.C. ... ruled "suicide"
(Natural News) A former executive for Pfizer, recently tasked with joining HHS to help reduce the prices of Big Pharma’s monopoly prescription medications, was found bludgeoned to death outside his Washington D.C. apartment. Local police ruled the death of Daniel Best a suicide, raising immediate questions about how an individual can bludgeon himself to death... (Source: NaturalNews.com)
Source: NaturalNews.com - November 18, 2018 Category: Consumer Health News Source Type: news

Pfizer to raise U.S. drug prices in January after previously backing down
Pfizer Inc said on Friday that it plans to hike U.S. prices on 41 of its medicines in January, after walking back its previous planned price increases this summer under pressure from President Donald Trump. (Source: Reuters: Health)
Source: Reuters: Health - November 16, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Pfizer to raise drug prices in January
Pfizer plans to raise the list prices of 41 of its prescription drugs, or 10 percent of its portfolio, in January. According to The Wall Street Journal, citing an unnamed source, most of the planned increases will be 5 percent, while three of the drugs’ list prices will go up by 3 percent. One of the drug prices will go up by 9 percent, the report continued. The move won’t affect 90 percent of the New Y ork drug company’s portfolio, including newly approved medicines and sterile injectables. Earlier… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - November 16, 2018 Category: American Health Authors: Anthony Noto Source Type: news

Pfizer to raise drug prices in January
Pfizer plans to raise the list prices of 41 of its prescription drugs, or 10 percent of its portfolio, in January. According to The Wall Street Journal, citing an unnamed source, most of the planned increases will be 5 percent, while three of the drugs’ list prices will go up by 3 percent. One of the drug prices will go up by 9 percent, the report continued. The move won’t affect 90 percent of the New Y ork drug company’s portfolio, including newly approved medicines and sterile injectables. Earlier… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - November 16, 2018 Category: Biotechnology Authors: Anthony Noto Source Type: news

Pfizer raises drug prices despite Trump criticism
Pharmaceutical giant backed down on July increases but will go ahead in January (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - November 16, 2018 Category: Pharmaceuticals Source Type: news

Pfizer plans to increase U.S. drug prices in January
Pfizer Inc said on Friday that it plans to hike U.S. prices on 41 of its medicines in January, after walking back its previous price increases this summer under pressure from President Donald Trump. (Source: Reuters: Health)
Source: Reuters: Health - November 16, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Pfizer loses major patent battle in the U.K.
Lyrica has officially fallen off the patent cliff in Britain. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - November 14, 2018 Category: Pharmaceuticals Source Type: news

Pfizer loses drug patent fight in UK top court, may face claims
Pfizer lost the final round in a lengthy patent battle in Britain on Wednesday after the country's highest court ruled against it in a case involving its $5 billion-a-year pain drug Lyrica, exposing the company to possible financial claims. (Source: Reuters: Health)
Source: Reuters: Health - November 14, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Pfizer loses blockbuster drug patent fight in UK Supreme Court
Pfizer lost the final round in a long-running patent battle in Britain on Wednesday after the country's highest court ruled against it in a case involving its $5 billion-a-year pain drug Lyrica. (Source: Reuters: Health)
Source: Reuters: Health - November 14, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Kymera Therapeutics Announces $65 Million Series B Financing to Advance Pipeline of Targeted Protein Degraders in Oncology and Immunology
Series B financing led by 6 Dimensions Capital, Bessemer Venture Partners, and Pfizer Ventures Financing to enable the advancement of lead program into clinical development and support the progression of additional programs CAMBRIDGE, Mass., Nov. 13,... Biopharmaceuticals, Venture Capital, Personnel Kymera Therapeutics, Pegasus (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 13, 2018 Category: Pharmaceuticals Source Type: news

FDA issues warning over some EpiPen, EpiPen Jr.
Pfizer and Mylan are warning that some EpiPen and EpiPen Jr. auto-injectors may not quickly slide out of carrier tubes due to labels that aren't fully adhered. The labels on some EpiPen 0.3 mg and EpiPen Jr. 0.15 mg auto-injectors and generics could stick, not allowing people who need them in emergencies to access them easily. "Although these are rare instances, delay in administration of EpiPen, EpiPen Jr. and the authorized generic versions of these s trengths has a possibility of being associated… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - November 6, 2018 Category: Pharmaceuticals Authors: Paul J. Gough Source Type: news

FDA issues warning over some EpiPen, EpiPen Jr.
Pfizer and Mylan are warning that some EpiPen and EpiPen Jr. auto-injectors may not quickly slide out of carrier tubes due to labels that aren't fully adhered. The labels on some EpiPen 0.3 mg and EpiPen Jr. 0.15 mg auto-injectors and generics could stick, not allowing people who need them in emergencies to access them easily. "Although these are rare instances, delay in administration of EpiPen, EpiPen Jr. and the authorized generic versions of these s trengths has a possibility of being associated… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - November 6, 2018 Category: Biotechnology Authors: Paul J. Gough Source Type: news

FDA Approves Lorbrena (lorlatinib) for Previously-Treated ALK-Positive Metastatic Non-Small Cell Lung Cancer
November 2, 2018 Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved Lorbrena [lor-BREN-ah] (lorlatinib), a third-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI) for... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - November 2, 2018 Category: Drugs & Pharmacology Source Type: news

FDA approves Pfizer's treatment for certain lung cancer patients
Pfizer Inc said on Friday the U.S. Food and Drug Administration has approved its lung-cancer treatment for patients with a specific gene mutation who had been previously treated for an aggressive form of the disease. (Source: Reuters: Health)
Source: Reuters: Health - November 2, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Pfizer may sell women ’s health biz
Pfizer is considering the sale of its women ’s health portfolio as the drugmaker looks to focus on developing treatments with higher growth potential, according to Bloomberg sources. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - November 1, 2018 Category: Pharmaceuticals Source Type: news

Kansas Pfizer plant needs injection of 350 more workers
Pfizer Inc., one of the world's largest pharmaceutical companies, has a jobs gap problem. It needs to add 350 workers to its existing 2,000-person workforce in McPherson, Kan. But with a state unemployment rate of 3.3 percent and a town of just 13,200, the drug manufacturer is expanding its search parameters. According to The Associated Press, Pfizer has held job fairs in Wichita and Salina where it is searching for new employees for a variety of positions, including lots of engineers, production… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - November 1, 2018 Category: American Health Authors: Andrew Vaupel Source Type: news

Morning Break: Pfizer Snubs Trump;'Vaginal Seeding'; Trick-or-Meth
(MedPage Today) -- Health news and commentary from around the Web gathered by the MedPage Today staff (Source: MedPage Today Psychiatry)
Source: MedPage Today Psychiatry - October 31, 2018 Category: Psychiatry Source Type: news

Pfizer outlook dented by strong dollar and legacy drug unit
(Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - October 30, 2018 Category: Pharmaceuticals Source Type: news

Novartis announces clinical collaboration with Pfizer to advance the treatment of NASH
Novartis announced today that it has entered into a clinical development agreement with Pfizer which will include a study combining tropifexor and one or more Pfizer compounds for the treatment of NASH, including an Acetyl CoA-Carboxylase (ACC) Inhibitor (PF-05221304, a Diacylglycerol O-Acyltransferase 2 (DGAT2) Inhibitor (PF-06865571, and a Ketohexokinase (KHK) Inhibitor (PF-06835919). (Source: World Pharma News)
Source: World Pharma News - October 29, 2018 Category: Pharmaceuticals Tags: Featured Novartis Business and Industry Source Type: news

Novartis, Pfizer join forces on potentially lucrative fatty liver disease
Novartis AG and Pfizer Inc are teaming up to develop treatments for a liver disease many drug companies believe will become a hugely lucrative market, as it is tied to the obesity and diabetes epidemics. (Source: Reuters: Health)
Source: Reuters: Health - October 29, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Pfizer-Lilly non-opioid drug helps reduce osteoarthritis pain
A non-opioid drug developed by Pfizer and Eli Lilly met the main goals of a late-stage study, in which over half of the patients reported a significant reduction in osteoarthritis pain of the knee or hip. (Source: Reuters: Health)
Source: Reuters: Health - October 24, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Bain, Pfizer launch biotech startup to tackle brain disorders
Bain Capital LP and Pfizer Inc. have teamed up to launch a new biotech in the Boston area focused on neurological disorders, including Parkinson ’s and Alzheimer’s disease. The new company, called Cerevel Therapeutics LLC, is starting out with a $350 million investment from funds affiliated with Bain. In a release, Pfizer (NYSE: PFE) and Bain said that Cerevel “will be based in the Greater Boston area,” but did not specify where. F or Pfizer, Tuesday’s announcement marks a return, of sorts,… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - October 23, 2018 Category: American Health Authors: Max Stendahl Source Type: news

In 2014 They Battled For Control. Now Pfizer's Read And AstraZeneca's Soriot In Different Places
Unfortunately, AstraZeneca ’s revenue predictions have not lived up to Soriot’s promise. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - October 23, 2018 Category: Pharmaceuticals Authors: John LaMattina, Contributor Tags: NYSE:PFE NYSE:AZN NYSE:NVS OTCMKTS:RHHBY Source Type: news

In 2014 They Battled For Control. Now Pfizer's Read And AstraZeneca's Soriot In Different Places
Unfortunately, AstraZeneca ’s revenue predictions have not lived up to Soriot’s promise. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - October 23, 2018 Category: Pharmaceuticals Authors: John LaMattina, Contributor Tags: NYSE:PFE NYSE:AZN NYSE:NVS OTCMKTS:RHHBY Source Type: news